Prognosis

Pfizer Falls as Covid Pill Fails in Preventive Therapy Trial

Pfizer’s Paxlovid antiviral medication — Pfizer’s Paxlovid antiviral medication
Photographer: Kobi Wolf/Bloomberg

Provide news feedback or report an error

Confidential tip?

Send a tip to our reporters

Site feedback:

Take our Survey

By John Lauerman

May 2, 2022 at 1:02 PM UTC

Updated on

May 2, 2022 at 1:39 PM UTC

This article is for subscribers only.

Pfizer Inc. slumped after Paxlovid, its pill for treating Covid-19, failed to show benefit as a preventive therapy in a trial.

Paxlovid is poised to become one of the fastest-selling drugs of all time, with $24 billion in projected 2022 sales, according to analytics group Airfinity Ltd. Pfizer has also reaped billions in global sales from its Covid-19 vaccine.